SAN FRANCISCO--(BUSINESS WIRE)--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and GenScript Biotech Corporation ...
CellProthera will use Quintessence’s DACSTM flotation‑based cell sorting platform for its potential to enhance therapeutic purity and preserve stem cell phenotype for CD34+-based cell therapy Mulhouse ...
Under the agreement, Northway Biotech will leverage its expertise in biologics manufacturing to develop and scale the production process for ATL-105 using the Pichia pastoris expression system. “With ...
The pharmaceutical contract manufacturing market is driven by increased outsourcing of complex processes to CMOs, enabling ...
Given the complexity of alternative-protein manufacturing, many biotech companies are exploring how to reduce costs with AI technologies, process improvements and novel uses for waste streams from ...
MaxCyte and Ori Biotech Forge Strategic Partnership to Enhance Cell Therapy Manufacturing Efficiency
MaxCyte, Inc. and Oribiotech Ltd. have announced a strategic collaboration to improve efficiency and scalability in cell therapy manufacturing. This partnership will integrate MaxCyte's ExPERT™ ...
Issued on behalf of Avaí Bio, Inc. VANCOUVER, BC, March 27, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary — The global cell therapy manufacturing market is hitting a pivotal inflection point.
Process validation plays a critical role in the success for a new biopharmaceutical on the path of commercialization, including the crucial process characterization. As a program advances towards ...
New K-NIBRT training hub addresses South Korea's critical biotech workforce shortage, graduating 3,400+ students in 2025 to ...
Key opportunities in the pharmaceutical manufacturing software market include leveraging AI and ML integration, cloud adoption, and expansion of smart manufacturing facilities. There's potential in ...
Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsin Lead indication is non-CF bronchiectasis; ATL-105 targets disease drivers through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results